Cancer Biomarkers and Oncoviruses examines the extensive clinical applications of biomarkers in cancer research, with a particular focus on oncoviruses. The book explores key topics such as cancer risk assessment, screening, and early detection. It further covers accurate diagnosis, patient prognosis, prediction of response to therapy, and cancer surveillance and monitoring. In 47 detailed chapters, Cancer Biomarkers and Oncoviruses presents the molecular biology and pathogenesis of viral oncology, the mechanisms of viral oncogenesis in humans, signaling pathways, and therapeutic options such as vaccines. It also discusses the future of cancer therapy involving oncoviruses.
The present book also covers critical analyses of cost savings in healthcare, respiratory biomarkers in viral infections, and lessons learned from the COVID-19 pandemic, focusing on pandemic preparedness, early detection, surveillance, and response strategies. These discussions aim to provide valuable insights into how lessons from the pandemic can be applied to improve healthcare systems and response strategies for both viral infections and cancer, helping inform future health management practices.
This book is an invaluable resource for health professionals, scientists, researchers, health practitioners, students, and anyone seeking to deepen their understanding in the field of cancer and virology. It offers valuable state-of-the-art insights, incorporating the latest research and cutting-edge developments in the field.
1. Introduction the different molecular aspects of tumor biomarkers and viral therapy of various tumors - p. li 2. Part 1: Cancers: genetic insights, molecular mechanisms, and emerging therapies - p. P1 3. Chapter 1. Breast cancer and new methods for treatment - p. 3 4. Chapter 2. The role of genetic markers P53, BRCA1, and BRCA2 in breast cancer risk assessment in women - p. 15 5. Chapter 3. MicroRNAs as key regulators of hormone dependent pathways in breast cancer - p. 29 6. Part 2: Lung and prostate cancer: genetic abnormalities and biomarkers - p. P43 7. Chapter 4. Genetic abnormalities of the EGFR pathway in the Middle East and North African patients with non-small cell lung cancer - p. 45 8. Chapter 5. MicroRNAs: advances in biomarkers, diagnostics, and therapeutic strategies in prostate cancer - p. 63 9. Part 3: HPV and cervical cancer: screening, prevention, and molecular mechanisms - p. P83 10. Chapter 6. Human papillomavirus infections in cervical cells for cervical cancer screening - p. 85 11. Chapter 7. MicroRNA and human herpesvirus 8 oncovirus in prostate cancer - p. 99 12. Part 4: Vitamin D and immune modulation in cancer - p. P113 13. Chapter 8. Prostate cancer antigen 3 as a diagnostic, prognostic, and therapeutic biomarker in prostate cancer - p. 115 14. Chapter 9. Interaction of the vitamin D in cancer development and progression - p. 121 15. Part 5: Emerging therapies and biomarkers in cancer - p. P137 16. Chapter 10. Study of the role of microRNAs in epstein barr virus induced prostate carcinogenesis - p. 139 17. Chapter 11. Addressing the burden of human papillomavirus-related cancers in North Africa: epidemiology, sociocultural barriers and prevention strategies - p. 147 18. Part 6: Management of the COVID-19 pandemic: lessons learned, surveillance, and respiratory biomarkers in SARS-CoV-2 pathogenesis - p. P161 19. Chapter 12. Management of the COVID-19 pandemic in Skhirate-Temara, Morocco: lessons in preparedness, surveillance, and rapid response - p. 163 20. Chapter 13. Respiratory biomarkers in the pathogenesis of SARS-CoV-2 - p. 179 21. Part 7: Viral miRNAs and oncoviruses: diagnostic, prognostic biomarkers, and therapeutic implications in cancer - p. P187 22. Chapter 14. Oncoviruses and cancer biomarkers: current and future perspectives - p. 189 23. Chapter 15. MicroRNAs in cancer development: biomarkers, functions and therapy - p. 201 24. Chapter 16. Viral miRNA’s: unlocking new frontiers in virus-induced cancers - p. 207 25. Part 8: Genetic and molecular basis of cancer - p. P231 26. Chapter 17. Molecular alterations involved in lung cancer - p. 233 27. Chapter 18. Oncogenic BRAF in prostate cancer: exosomes and miRNA status and implications for targeted therapy - p. 243 28. Chapter 19. Targeted therapy in prostate and bladder cancer—role of BRAF and RAS mutations - p. 251 29. Chapter 20. In-depth analysis of tumor markers in leukemia - p. 259 30. Part 9: Molecular mechanisms and therapeutic implications in cancer - p. P273 31. Chapter 21. Nasopharyngeal cancer associated with epstein barr virus - p. 275 32. Chapter 22. Molecular mechanisms of cervical cancer - p. 283 33. Part 10: Economic and market analysis in cancer research - p. P307 34. Chapter 23. Critical analysis of the cost savings generated by biomarkers and oncoviruses in healthcare - p. 309 35. Chapter 24. Market analysis of exosome technologies for the diagnosis of genitourinary cancers - p. 327 36. Part 11: Phage therapy and immune modulation - p. P347 37. Chapter 25. Phagotherapy: The discreet power of our immune cells - p. 349 38. Part 12: Emerging therapies and biomarkers in cancer - p. P363 39. Chapter 26. Mechanism of resistance to platinum salt-based chemotherapy - p. 365 40. Chapter 27. Marine algae as a source of bioactive compounds: unlocking anticancer potential - p. 375 41. Chapter 28. Cervical cancer: new treatment approaches using microRNA - p. 391 42. Chapter 29. Therapeutic potential of the intratumoral microbiota in tumors - p. 409 43. Chapter 30. Molecular biomarkers in bladder cancer: identification and clinical relevance - p. 419 44. Chapter 31. Emerging biomarker applications for precision targeting in bladder cancer therapy - p. 429 45. Chapter 32. Fusion gene and cancer - p. 441 46. Chapter 33. Immunotherapy biomarkers in melanoma: fromprogrammed death-ligand 1 expression to tumor mutational burden - p. 453 47. Chapter 34. The role of vitamin D supplementation in cancer treatment - p. 467 48. Chapter 35. The role of vitamin D in modulating immune responses against oncoviruses human papillomavirus, Epstein–Barr virus, and human herpesvirus-8 - p. 481 49. Part 13: Epigenetics and DNA methylation in cancer - p. P493 50. Chapter 36. Post-transcriptional epigenetic marks: DNA and microRNA methylation - p. 495 51. Chapter 37. Epigenetic mechanism induced by human herpesvirus 8 in prostate cancer - p. 503 52. Chapter 38. Role of methylation DNA in cell regulation - p. 517 53. Chapter 39. DNA methylation biomarkers in colorectal cancer - p. 527 54. Part 14: Oncoviruses and viral-associated cancers - p. P539 55. Chapter 40. Deciphering the molecular tapestry: extracellular vesicles as pioneering biomarker reservoirs for precision therapy in urogenital cancers - p. 541 56. Chapter 41. Retroviruses as biomarkers in prostate carcinoma - p. 559 57. Chapter 42. The role of breast cancer gene 1 and breast cancer gene 2 in determining breast cancer therapy - p. 565 58. Chapter 43. The biomarkers landscape in lung cancer: implication for diagnosis, prediction, and prognosis - p. 571 59. Chapter 44. Human papillomavirus as the main cause of cervical cancer: diagnosis, treatment, and prevention - p. 653 60. Chapter 45. Oncogenic role of proline-rich protein 11 in breast and gynecologic cancers: mechanisms, signaling pathways, and therapeutic implications - p. 667 61. Chapter 46. MicroRNAs as biomarkers in gynecological-mammary cancers - p. 679 62. Chapter 47. Proline-rich protein 11 as a diagnosis and prognosis biomarker in breast and cervical cancers - p. 697 63. Chapter 48. Recent advances in therapy and biomarkers: triple negative breast cancer - p. 713 64. Chapter 49. Recent advances in exosome-based therapies for prostate cancer: targeting oncoviral and epigenetic pathways - p. 741 65. Chapter 50. Exosomes as carriers of viral and host biomarkers in virus-associated gynecological cancers - p. 759 66. Conclusion - p. 779 67. Author index - p. 781 68. Subject index - p. 803
Cancer Biomarkers and Oncoviruses examines the extensive clinical applications of biomarkers in cancer research, with a particular focus on oncoviruses. The book explores key topics such as cancer risk assessment, screening, and early detection. It further covers accurate diagnosis, patient prognosis, prediction of response to therapy, and cancer surveillance and monitoring. In 47 detailed chapters, Cancer Biomarkers and Oncoviruses presents the molecular biology and pathogenesis of viral oncology, the mechanisms of viral oncogenesis in humans, signaling pathways, and therapeutic options such as vaccines. It also discusses the future of cancer therapy involving oncoviruses.
The present book also covers critical analyses of cost savings in healthcare, respiratory biomarkers in viral infections, and lessons learned from the COVID-19 pandemic, focusing on pandemic preparedness, early detection, surveillance, and response strategies. These discussions aim to provide valuable insights into how lessons from the pandemic can be applied to improve healthcare systems and response strategies for both viral infections and cancer, helping inform future health management practices.
This book is an invaluable resource for health professionals, scientists, researchers, health practitioners, students, and anyone seeking to deepen their understanding in the field of cancer and virology. It offers valuable state-of-the-art insights, incorporating the latest research and cutting-edge developments in the field.
1. Introduction the different molecular aspects of tumor biomarkers and viral therapy of various tumors - p. li 2. Part 1: Cancers: genetic insights, molecular mechanisms, and emerging therapies - p. P1 3. Chapter 1. Breast cancer and new methods for treatment - p. 3 4. Chapter 2. The role of genetic markers P53, BRCA1, and BRCA2 in breast cancer risk assessment in women - p. 15 5. Chapter 3. MicroRNAs as key regulators of hormone dependent pathways in breast cancer - p. 29 6. Part 2: Lung and prostate cancer: genetic abnormalities and biomarkers - p. P43 7. Chapter 4. Genetic abnormalities of the EGFR pathway in the Middle East and North African patients with non-small cell lung cancer - p. 45 8. Chapter 5. MicroRNAs: advances in biomarkers, diagnostics, and therapeutic strategies in prostate cancer - p. 63 9. Part 3: HPV and cervical cancer: screening, prevention, and molecular mechanisms - p. P83 10. Chapter 6. Human papillomavirus infections in cervical cells for cervical cancer screening - p. 85 11. Chapter 7. MicroRNA and human herpesvirus 8 oncovirus in prostate cancer - p. 99 12. Part 4: Vitamin D and immune modulation in cancer - p. P113 13. Chapter 8. Prostate cancer antigen 3 as a diagnostic, prognostic, and therapeutic biomarker in prostate cancer - p. 115 14. Chapter 9. Interaction of the vitamin D in cancer development and progression - p. 121 15. Part 5: Emerging therapies and biomarkers in cancer - p. P137 16. Chapter 10. Study of the role of microRNAs in epstein barr virus induced prostate carcinogenesis - p. 139 17. Chapter 11. Addressing the burden of human papillomavirus-related cancers in North Africa: epidemiology, sociocultural barriers and prevention strategies - p. 147 18. Part 6: Management of the COVID-19 pandemic: lessons learned, surveillance, and respiratory biomarkers in SARS-CoV-2 pathogenesis - p. P161 19. Chapter 12. Management of the COVID-19 pandemic in Skhirate-Temara, Morocco: lessons in preparedness, surveillance, and rapid response - p. 163 20. Chapter 13. Respiratory biomarkers in the pathogenesis of SARS-CoV-2 - p. 179 21. Part 7: Viral miRNAs and oncoviruses: diagnostic, prognostic biomarkers, and therapeutic implications in cancer - p. P187 22. Chapter 14. Oncoviruses and cancer biomarkers: current and future perspectives - p. 189 23. Chapter 15. MicroRNAs in cancer development: biomarkers, functions and therapy - p. 201 24. Chapter 16. Viral miRNA’s: unlocking new frontiers in virus-induced cancers - p. 207 25. Part 8: Genetic and molecular basis of cancer - p. P231 26. Chapter 17. Molecular alterations involved in lung cancer - p. 233 27. Chapter 18. Oncogenic BRAF in prostate cancer: exosomes and miRNA status and implications for targeted therapy - p. 243 28. Chapter 19. Targeted therapy in prostate and bladder cancer—role of BRAF and RAS mutations - p. 251 29. Chapter 20. In-depth analysis of tumor markers in leukemia - p. 259 30. Part 9: Molecular mechanisms and therapeutic implications in cancer - p. P273 31. Chapter 21. Nasopharyngeal cancer associated with epstein barr virus - p. 275 32. Chapter 22. Molecular mechanisms of cervical cancer - p. 283 33. Part 10: Economic and market analysis in cancer research - p. P307 34. Chapter 23. Critical analysis of the cost savings generated by biomarkers and oncoviruses in healthcare - p. 309 35. Chapter 24. Market analysis of exosome technologies for the diagnosis of genitourinary cancers - p. 327 36. Part 11: Phage therapy and immune modulation - p. P347 37. Chapter 25. Phagotherapy: The discreet power of our immune cells - p. 349 38. Part 12: Emerging therapies and biomarkers in cancer - p. P363 39. Chapter 26. Mechanism of resistance to platinum salt-based chemotherapy - p. 365 40. Chapter 27. Marine algae as a source of bioactive compounds: unlocking anticancer potential - p. 375 41. Chapter 28. Cervical cancer: new treatment approaches using microRNA - p. 391 42. Chapter 29. Therapeutic potential of the intratumoral microbiota in tumors - p. 409 43. Chapter 30. Molecular biomarkers in bladder cancer: identification and clinical relevance - p. 419 44. Chapter 31. Emerging biomarker applications for precision targeting in bladder cancer therapy - p. 429 45. Chapter 32. Fusion gene and cancer - p. 441 46. Chapter 33. Immunotherapy biomarkers in melanoma: fromprogrammed death-ligand 1 expression to tumor mutational burden - p. 453 47. Chapter 34. The role of vitamin D supplementation in cancer treatment - p. 467 48. Chapter 35. The role of vitamin D in modulating immune responses against oncoviruses human papillomavirus, Epstein–Barr virus, and human herpesvirus-8 - p. 481 49. Part 13: Epigenetics and DNA methylation in cancer - p. P493 50. Chapter 36. Post-transcriptional epigenetic marks: DNA and microRNA methylation - p. 495 51. Chapter 37. Epigenetic mechanism induced by human herpesvirus 8 in prostate cancer - p. 503 52. Chapter 38. Role of methylation DNA in cell regulation - p. 517 53. Chapter 39. DNA methylation biomarkers in colorectal cancer - p. 527 54. Part 14: Oncoviruses and viral-associated cancers - p. P539 55. Chapter 40. Deciphering the molecular tapestry: extracellular vesicles as pioneering biomarker reservoirs for precision therapy in urogenital cancers - p. 541 56. Chapter 41. Retroviruses as biomarkers in prostate carcinoma - p. 559 57. Chapter 42. The role of breast cancer gene 1 and breast cancer gene 2 in determining breast cancer therapy - p. 565 58. Chapter 43. The biomarkers landscape in lung cancer: implication for diagnosis, prediction, and prognosis - p. 571 59. Chapter 44. Human papillomavirus as the main cause of cervical cancer: diagnosis, treatment, and prevention - p. 653 60. Chapter 45. Oncogenic role of proline-rich protein 11 in breast and gynecologic cancers: mechanisms, signaling pathways, and therapeutic implications - p. 667 61. Chapter 46. MicroRNAs as biomarkers in gynecological-mammary cancers - p. 679 62. Chapter 47. Proline-rich protein 11 as a diagnosis and prognosis biomarker in breast and cervical cancers - p. 697 63. Chapter 48. Recent advances in therapy and biomarkers: triple negative breast cancer - p. 713 64. Chapter 49. Recent advances in exosome-based therapies for prostate cancer: targeting oncoviral and epigenetic pathways - p. 741 65. Chapter 50. Exosomes as carriers of viral and host biomarkers in virus-associated gynecological cancers - p. 759 66. Conclusion - p. 779 67. Author index - p. 781 68. Subject index - p. 803
